TMO

Thermo Fisher Scientific Inc. (TMO) | Rumor.io

Thermo Fisher Scientific

TMO

Attention (50-day avg)0%

Attention rank (50-day avg)#720

Bullish sentiment (50-day avg)88%

Price to earnings ratio36.4

Market capitalization250.9B

Earnings per share18.6

Dividend yield (TTM)0.28%

Revenue (annual)44.6B

Net income (annual)6.7B

Social

What share of all stock conversation is about TMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% -0.01

Aug 19

Thermo Fisher Scientific has consistently delivered or overdelivered relative to expectations before the COVID period, and may be back to business as usual with end markets slowly recovering.
The company has a strong backlog, is testing with major partners, and has huge revenue opportunities from government contracts starting in 2027.
Thermo Fisher Scientific is becoming a critical infrastructure provider for the global life-sciences industry, supplying instruments, diagnostics, and biopharma manufacturing solutions.

Generated by AI

Sentiment

Of the messages about TMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +13.64	89.5% +2.52	72.53% -21.07
Bearish	—	0% -13.64	10.5% -2.52	27.47% +21.07

Bullish· Jul 23

The company has delivered outstanding performance in the second quarter, with revenue growth accelerating to 10% YoY and Adjusted EPS surging 13% to $6.03.
Thermo Fisher Scientific has successfully executed its growth strategy centered on innovation, customer partnerships, and commercial capabilities, benefiting from the recovery of demand by biotech and pharmaceutical companies.
The company has demonstrated robust performance across its segments, leading to an upward revision in guidance, with revenue of $11.99B growing 10% YoY and exceeding expectations as end-market strength drove broad-based growth.

Bearish· Jan 31

Thermo Fisher's stock price fell 2% after the company issued subdued annual outlook and forecasted 2024 profit below estimates.
The company's Q4 organic sales declined 7%, and the medical equipment maker's 2024 guidance trailed analyst estimates.
Thermo Fisher's stock price is moderately expensive relative to history, with a forward earnings multiple of 26x, following two quarters of earnings write-downs.

Generated by AI

Topics

Of the messages about TMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	10.81%	17.89%
Technical Analysis	—	100%	42.16%	3.79%
Macro	—	0%	19.46%	34.73%
Earnings	—	0%	0.54%	5.93%
Analysts	—	0%	23.24%	37.32%
Controversies	—	0%	3.78%	0.34%

Earnings· Jan 29

Thermo Fisher Scientific Inc. ($TMO) reported Q4 2025 earnings, with adjusted EPS of $6.57, beating the estimate of $6.45, and revenue of $12.21B, beating the estimate of $11.95B.
The company's Q4 revenue increased 7.2% year-over-year, with adjusted net income rising 9% to $2.48B.
Thermo Fisher Scientific's strong Q4 performance was driven by excellent operational execution, share gains, and the power of its growth strategy and PPI Business System.

Analysts· Feb 2

Analysts at SVB Leerink raised Thermo Fisher Scientific's price target to $560.00 with an outperform rating.
Multiple analysts, including Morgan Stanley, UBS, and Citigroup, have raised Thermo Fisher Scientific's price target, with estimates ranging from $530.00 to $588.00.
Analysts at various firms, including Cowen, Stifel Nicolaus, and Jefferies, have also raised Thermo Fisher Scientific's price target, with estimates ranging from $525.00 to $600.00.

Announcements· Jan 30

Thermo Fisher Scientific Inc. (TMO) is a beneficiary of AI adoption in supply chains.
TMO positions as a company that aligns with enterprise digital transformation trends in logistics.
TMO's trend momentum is related to the trend momentum of NextNRG, Inc. (NXXT).

Generated by AI

Community

Of the messages about TMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	51.9%	14.25%	34.55%
Newcomers	—	48.1%	85.75%	65.45%

Regulars· Jul 23

TMO's Q2 earnings report shows revenue of $11.99B, beating estimates of $11.7B, with a 10% YoY increase and 5% organic revenue growth.
The company's adjusted EPS came in at $6.03, surpassing estimates of $5.71, with a 13% YoY increase.
TMO's CEO highlights the company's "outstanding performance" in Q2, with broad-based growth across end markets, and raises full-year guidance, citing successful execution of its growth strategy.

Newcomers· Jul 23

$TMO rose 8.5% after strong Q2 2026 earnings, beating revenue and EPS estimates with adjusted EPS of $6.03, a 13% YoY increase.
The company's adjusted operating margin expanded 90bps to 22.8%, and free cash flow surged 52% to $1.68B, with organic growth reaccelerating to 5% in Q2.
The stock's price is supported by the earnings beat and signs of strengthening customer activity, prompting investors and analysts to raise near-term revenue and profit expectations.

Generated by AI

Thermo Fisher Scientific has been a strong performer over the past year, and that kind of run naturally raises a pointed question for anyone looking at the stock today. Is the current share price aligned with the cash flows the business is expected to generate, or has sentiment moved ahead of the underlying economics? The stock has returned 47.4% over the past year, which puts real pressure on the question of whether the current valuation still lines up with the cash being produced and...

1d agofinance.yahoo.com

Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?

On September 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel enables […]

1d agofinance.yahoo.com

Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...

1d agoYahoo Finance

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]

1d agoYahoo Finance

Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno

Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflowsSINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global leader in standardized proteomics solutions, today announced a reseller agreement with Thermo Fisher Scientific, the world leader in serving science. Through this agreement, Thermo Fisher Scientific will offer the Evosep Eno™ separation platform as part of its portfolio of mass spec

2d agoYahoo Finance UK

Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as […]

2d agoYahoo Finance

Also Discussed

Investors talking about TMO also mention

#	Name	Attention
1	Danaher Corp.DHR	0.02%+0.02
2	Qiagen N.V.QGEN	0%+0
3	Quest Diagnostics IncorporatedDGX	0%0
4	Mainz Biomed N.V.MYNZ	0%new
5	Illumina Inc.ILMN	0%+0
6	Stryker CorporationSYK	0.01%+0.01
7	Labcorp Holdings Inc.LH	0%0
8	OLK - Olink Holding AB (publ)	——
9	Guardant Health Inc.GH	0%-0.11
10	Mettler-Toledo International Inc.MTD	0%new

Thermo Fisher Scientific Inc.

Healthcare
Diagnostics & Research

Thermo Fisher Scientific Inc. is a life sciences and laboratory solutions company that provides the tools and services used in research, diagnostics, and biopharmaceutical manufacturing. Its portfolio spans analytical instruments, laboratory equipment, reagents, consumables, software, and specialized services that support scientific workflows from sample preparation and analysis to clinical testing and production. The company serves pharmaceutical and biotechnology firms, hospitals, clinical laboratories, universities, research institutions, and industrial customers across environmental and quality-control applications. Thermo Fisher Scientific operates through four main businesses: Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions, and Specialty Diagnostics. It plays a central role in the global scientific infrastructure by supplying products and services that help customers generate data, improve laboratory productivity, and support research and diagnostic operations worldwide.

Website

Location

168 Third Avenue

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about TMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% -0.01

Aug 19

Thermo Fisher Scientific has consistently delivered or overdelivered relative to expectations before the COVID period, and may be back to business as usual with end markets slowly recovering.
The company has a strong backlog, is testing with major partners, and has huge revenue opportunities from government contracts starting in 2027.
Thermo Fisher Scientific is becoming a critical infrastructure provider for the global life-sciences industry, supplying instruments, diagnostics, and biopharma manufacturing solutions.

Generated by AI

Sentiment

Of the messages about TMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +13.64	89.5% +2.52	72.53% -21.07
Bearish	—	0% -13.64	10.5% -2.52	27.47% +21.07

Bullish· Jul 23

The company has delivered outstanding performance in the second quarter, with revenue growth accelerating to 10% YoY and Adjusted EPS surging 13% to $6.03.
Thermo Fisher Scientific has successfully executed its growth strategy centered on innovation, customer partnerships, and commercial capabilities, benefiting from the recovery of demand by biotech and pharmaceutical companies.
The company has demonstrated robust performance across its segments, leading to an upward revision in guidance, with revenue of $11.99B growing 10% YoY and exceeding expectations as end-market strength drove broad-based growth.

Bearish· Jan 31

Thermo Fisher's stock price fell 2% after the company issued subdued annual outlook and forecasted 2024 profit below estimates.
The company's Q4 organic sales declined 7%, and the medical equipment maker's 2024 guidance trailed analyst estimates.
Thermo Fisher's stock price is moderately expensive relative to history, with a forward earnings multiple of 26x, following two quarters of earnings write-downs.

Generated by AI

Topics

Of the messages about TMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	10.81%	17.89%
Technical Analysis	—	100%	42.16%	3.79%
Macro	—	0%	19.46%	34.73%
Earnings	—	0%	0.54%	5.93%
Analysts	—	0%	23.24%	37.32%
Controversies	—	0%	3.78%	0.34%

Earnings· Jan 29

Thermo Fisher Scientific Inc. ($TMO) reported Q4 2025 earnings, with adjusted EPS of $6.57, beating the estimate of $6.45, and revenue of $12.21B, beating the estimate of $11.95B.
The company's Q4 revenue increased 7.2% year-over-year, with adjusted net income rising 9% to $2.48B.
Thermo Fisher Scientific's strong Q4 performance was driven by excellent operational execution, share gains, and the power of its growth strategy and PPI Business System.

Analysts· Feb 2

Analysts at SVB Leerink raised Thermo Fisher Scientific's price target to $560.00 with an outperform rating.
Multiple analysts, including Morgan Stanley, UBS, and Citigroup, have raised Thermo Fisher Scientific's price target, with estimates ranging from $530.00 to $588.00.
Analysts at various firms, including Cowen, Stifel Nicolaus, and Jefferies, have also raised Thermo Fisher Scientific's price target, with estimates ranging from $525.00 to $600.00.

Announcements· Jan 30

Thermo Fisher Scientific Inc. (TMO) is a beneficiary of AI adoption in supply chains.
TMO positions as a company that aligns with enterprise digital transformation trends in logistics.
TMO's trend momentum is related to the trend momentum of NextNRG, Inc. (NXXT).

Generated by AI

Community

Of the messages about TMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	51.9%	14.25%	34.55%
Newcomers	—	48.1%	85.75%	65.45%

Regulars· Jul 23

TMO's Q2 earnings report shows revenue of $11.99B, beating estimates of $11.7B, with a 10% YoY increase and 5% organic revenue growth.
The company's adjusted EPS came in at $6.03, surpassing estimates of $5.71, with a 13% YoY increase.
TMO's CEO highlights the company's "outstanding performance" in Q2, with broad-based growth across end markets, and raises full-year guidance, citing successful execution of its growth strategy.

Newcomers· Jul 23

$TMO rose 8.5% after strong Q2 2026 earnings, beating revenue and EPS estimates with adjusted EPS of $6.03, a 13% YoY increase.
The company's adjusted operating margin expanded 90bps to 22.8%, and free cash flow surged 52% to $1.68B, with organic growth reaccelerating to 5% in Q2.
The stock's price is supported by the earnings beat and signs of strengthening customer activity, prompting investors and analysts to raise near-term revenue and profit expectations.

Generated by AI

Thermo Fisher Scientific

Social

Aug 19

Bullish· Jul 23

Bearish· Jan 31

Earnings· Jan 29

Analysts· Feb 2

Announcements· Jan 30

Regulars· Jul 23

Newcomers· Jul 23

Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run

Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?

Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno

Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?

Also Discussed

Thermo Fisher Scientific Inc.

Company Information

Location

Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run

Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow?

Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative

Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?

Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno

Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?

Also Discussed

Social

Aug 19

Bullish· Jul 23

Bearish· Jan 31

Earnings· Jan 29

Analysts· Feb 2

Announcements· Jan 30

Regulars· Jul 23

Newcomers· Jul 23